CAJ | 학술논문

目的研究胰腺癌中次级淋巴组织趋化因子(SLC)及其受体CCR7的表达情况,探讨其在胰腺癌淋巴管生成中的作用.方法采用免疫组织化学和RT-PCR方法检测30例胰腺痛病灶、癌旁组织、正常胰腺和胰周淋巴结中的中SLC、CCR7的表达情况,形态计量学图像分析法测定胰腺癌中微淋巴管密度(MLVD),分析其表达与胰腺癌MLVD间的关系.结果 SLC蛋白在胰腺癌组织、癌旁组织、胰周淋巴结、正常胰腺组织中的阳性率分别为16.7%、43.3%、46.6%和76.7%.CCR7蛋白在上述组织中阳性率分别为76.7%、66.7%、70.0%和30.0%;RT-PeR表明SLC、CCR7 mRNA表达与其蛋白表达强度相同.胰腺癌SLC阳性组与阴性组中MLVD无明显差异(P>0.05),CCR7阳性组中MLVD明显高于阴性组(P=0.004).结论 SLC与胰腺癌的分期及转移无关,CCR7的表达与胰腺癌TNM分期和淋巴结转移密切相关,其高表达对胰腺癌中淋巴管生成及淋巴结转移可能起促进作用.
목적 연구이선암중차급림파조직추화인자(SLC)급기수체CCR7적표체정황,탐토기재이선암림파관생성중적작용.방법 채용면역조직화학화RT-PCR방법검측30례이선통병조、암방조직、정상이선화이주림파결중적중SLC、CCR7적표체정황,형태계량학도상분석법측정이선암중미림파관밀도(MLVD),분석기표체여이선암MLVD간적관계.결과 SLC단백재이선암조직、암방조직、이주림파결、정상이선조직중적양성솔분별위16.7%、43.3%、46.6%화76.7%.CCR7단백재상술조직중양성솔분별위76.7%、66.7%、70.0%화30.0%;RT-PeR표명SLC、CCR7 mRNA표체여기단백표체강도상동.이선암SLC양성조여음성조중MLVD무명현차이(P>0.05),CCR7양성조중MLVD명현고우음성조(P=0.004).결론 SLC여이선암적분기급전이무관,CCR7적표체여이선암TNM분기화림파결전이밀절상관,기고표체대이선암중림파관생성급림파결전이가능기촉진작용.
Objective To study the expression of secondary lymphoid-tissue chemokine (SLC)、 CCR7 and its correlation with clinical pathology and lymphangiogenesis in pancreatic adenocarcinoma (PAC). Methods The tissue specimens including PAC, the cancerous peripheral tissues, the normal pancreatic tissues and peripheral lymph nodes were obtained from 30 patients with PAC. The expressions of SLC and CCR7 in these tissues were assayed by immunohistochemical staining and reverse transcription polymerase chain reaction (RT-PCR). MIND marked by VEGFR-3 was detected by morphometric analysis, and the relationship between MLND and clinical pathology of PAC was analyzed. Results In all the specimens, the positive rates of SLC protein in PAC, the cancerous peripheral tissues, the normal pancreatic tissues and peripheral lymph nodes were respectively 16. 7%, 43. 3%, 76. 7% and 46. 6%. The positive rates of CCR7 protein in PAC, the cancerous peripheral tissues, the normal pancreatic tissues and peripheral lymph nodes were respectively 76. 7%, 66. 7%, 30. 0% and 70. 0%. The results of RT-PCR and fluorescence quantitative real-time PCR indicated that the expression levels of CCR7 mRNA in PAC tissues, the cancerous peripheral tissues and peripheral lymph nodes were higher than that in the normal pancreatic tissues ( P <0. 01 ). There was no significant correlation between the expression of SLC protein with MLVD of PAC ( P > 0. 05 ). There was 23 specimens that the CCR7 protein was positive, and among these specimens the MIND was higher than that in negative group of CCR7 protein (P = 0.004). Conclusions The expression of SLC was not related to lymphatic metastasis and TNM stages of PAC. The expression of CCR7 was significantly associated with lymphatic metastasis and TNM stages of PAC, and the high expression of CCR7 in PAC tissues was significantly associated with lymphangiogenesis of PAC.